This site is intended for health professionals only
Saturday 19 January 2019
Share |

Topic: Latest News

January 16, 2019
A university has been given more than £2m to conduct research into opiod overprescribing in the NHS.

A university has been given more than £2m to conduct research into opiod overprescribing in the NHS.
 

January 15, 2019
Academics and health professionals are combining their expertise to trial new technology which could speed up the diagnosis and treatment for thousands of hepatitis and HIV patients
 
Late diagnosis of blood-borne viruses (BBV), such as HIV and hepatitis, remains high in the UK despite efforts to increase testing among those at risk of infection.
 
Experts at Teesside University and South Tees Hospitals NHS Foundation Trust have developed a new software application to assist GPs and health-care workers to make decisions about BBV- testing in real time.
 
January 15, 2019
Sheffield Teaching Hospitals is one of 20 UK sites participating in a groundbreaking trial looking at whether an anti-sickness drug commonly given to patients having cancer treatments such as radiotherapy and chemotherapy could improve the lives of patients living with irritable bowel syndrome
Sheffield Teaching Hospitals NHS Foundation Trust has been named as one of 20 UK sites involved in a landmark trial assessing whether a drug commonly used to prevent nausea and sickness after surgery, radiotherapy or chemotherapy could help treat patients suffering with the agonising symptoms of irritable bowel syndrome.
 
January 8, 2019
Mosul, Iraq’s second city, is slowly rebuilding its healthcare infrastructure after years of war and destruction. Dr Henryk Pich, a consultant anaesthetist and intensive care physician at the University of Dresden, Germany, visited the region soon after the fighting had ended, supported by the independent aid organisation CADUS

Dr Henryk Pich spent time travelling in the Middle East as a young man. Not surprisingly, he feels a personal connection to the region and, after seeing the devastation caused by years of war to cities such as Mosul, wanted to offer whatever help he could.

He contacted CADUS, an independent German aid organisation building mobile clinics for areas with significant need and, once the fighting had ended, joined a highly skilled, inter-disciplinary team of paramedics, nurses, doctors, technicians and project managers working in Mosul.

January 8, 2019
New plans for the NHS to tackle ‘killer conditions’ such as strokes and heart attacks could save up to half a million lives, the UK’s Government has announced.

The NHS Long Term Plan, published today (7 January) outlines how over three million people will be treated from new stroke, respiratory and cardiac services over the next decade.
 
The measures, supported by £4.5bn in new service model funding, will help prevent over 150,000 heart attacks, strokes and cases of dementia, according to the plan.
 
Measures in the plan will also help over three million people through improved stroke, respiratory and cardiac services over the next 10 years, it said.
 

January 7, 2019
If approved, ustekinumab will be the first interleukin (IL)-12/23 inhibitor licensed for the treatment of ulcerative colitis

Janssen has announced the submission of a Group Type II Variation Application to the European Medicines Agency (EMA) seeking approval of Stelara® (ustekinumab) for the treatment of adults with moderately to severely active ulcerative colitis (UC).

Ustekinumab is a human monoclonal antibody that targets the interleukin (IL)-12 and IL-23 cytokines, which are believed to play an important role in the immune and inflammatory responses seen in immune-mediated diseases, such as UC and Crohn’s disease.1

January 7, 2019
NOVESA is planned to recruit 30 patients with diffuse cutaneous systemic sclerosis, an autoimmune disease involving multiorgan fibrosis, which has one of the highest mortality rates among rheumatic diseases
Galapagos NV has expanded its clinical study program with GLPG1690 in systemic sclerosis (SSc), following the recent start of the ISABELA Phase III program with ’1690 in idiopathic pulmonary fibrosis (IPF).
 
December 21, 2018
The Award encourages exceptional investigators worldwide to pursue innovative research projects that pair unconventional creativity with sound science to uncover the fundamental causes of lupus

The Lupus Research Alliance has announced the 2018 recipients of the Dr. William E. Paul Distinguished Innovator Award in Lupus and Autoimmunity: namely, Nir Hacohen, PhD and Vijay Kuchroo, DVM, PhD.

December 17, 2018
Omalizumab prefilled syringe is the first and only biologic to receive European Commission approval for self-administration in severe allergic asthma and chronic spontaneous urticaria
Novartis has announced that the European Commission (EC) has approved Xolair® (omalizumab) prefilled syringe (PFS) for self-administration, allowing patients with severe allergic asthma (SAA) and chronic spontaneous urticaria (CSU) to administer their own treatment.
 
With this approval, Xolair is the first and only biologic to offer the option of self-administration for SAA and CSU.
 
December 13, 2018
There is growing evidence that the composition of the microbiome is a promising predictive tool for disease and for patient response to therapy in conditions such as IBD, cancer and liver disease
BiomX Ltd, a microbiome company developing customised phage therapies,  has entered into a collaboration with Janssen Research & Development to utilise BiomX’s XMarker microbiome-based biomarker discovery platform. The XMarker platform will be used to stratify responders and non-responders to inflammatory bowel disease (IBD) therapeutics.
 
The collaboration was facilitated by Johnson & Johnson Innovation Limited.
 
December 12, 2018
The Government has chosen England’s chief pharmacist to look into ‘problematic’ overprescribing in the NHS, it has announced.

The Government has chosen England’s chief pharmacist to look into "problematic" overprescribing in the NHS, it has announced.
 

December 11, 2018
A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.

A no-deal Brexit could create disruption over importing and exporting medicines at the Anglo-French border for up to six months, the Government has predicted.
 
In a letter published on 7 December, health and social care secretary Matt Hancock said Britain exiting the European Union without a deal will "significantly" reduce access across the channel for "up to six months".
 

December 10, 2018
The Joint Cancer Research UK - AstraZeneca Functional Genomics Centre will be a dedicated world-class resource for AstraZeneca and Cancer Research UK’s academics and alliance partners working at all stages of translational research, from target discovery and validation, to assessing novel drug combinations
Cancer Research UK and AstraZeneca have announced that they are opening a new centre in the UK, dedicated to realising the full potential of functional genomics in the discovery and development of new drugs for patients with cancer.
 
This partnership will explore in more detail the function and interaction of genes and proteins in cancer, and apply new genome-altering technologies such as CRISPR, to create sophisticated models of the disease for research.
 
December 7, 2018
Novartis's BYL719 is in late-stage development, and Qiagen expects to provide its companion diagnostic to clinical laboratory partners who will then be ready to offer immediate access to the test upon potential regulatory approvals

Qiagen has announced that a clinical development programme is underway with Novartis to bring to market a molecular test as a companion diagnostic to guide the use of the investigational compound BYL719 (alpelisib) in combination with fulvestrant for men and postmenopausal women living with PIK3CA mutated hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced or metastatic breast cancer.

December 6, 2018
Delays in taking new cancer drugs through clinical trials and getting them approved for use mean NHS patients are waiting longer to access them, a report by the Institute of Cancer Research (ICR) finds.

NHS patients are waiting longer for new cancer drugs because of delays in taking them through clinical trials and getting them approved for use, a new report has revealed.

The average time from when a cancer drug is patented to approval by NICE increased from 12.7 years between 2000-08 to 14.1 years between 2009-16, The Institute of Cancer Research, London (ICR) found.

December 6, 2018
Research shows 31% of medication administration errors in English and Welsh acute care trusts are due to omitted medicine or ingredient.

Three in 10 drug-related deaths occurring in acute care settings are caused by omission, a study has revealed.
 

December 6, 2018
Leading academics and health data specialists have formed an alliance to boost science and innovation in the UK

The UK’s leading academics and health data specialists have formed an alliance to develop new ways to design and support the medical research of the future, and to improve the care patients receive from the NHS.
 
The UK Health Data Research Alliance will look atthe best ways to design, use, collect, manage and analyse health data in a responsible way for clinical trials, medical research, and innovation.
 

December 3, 2018
An opinion from the CHMP is expected in the second half of 2019

Celltrion has announced that the European Medicines Agency (EMA) has accepted for review of the Extension Marketing Authorisation Application for ‘Remsima SC’, the subcutaneous (SC) version of Remsima®, the autoimmune disease therapeutic antibody biosimilar of infliximab.

November 30, 2018
Researchers exposed lung, ovarian and colon cancer cells, and mouse models, to conditions similar to those in the human body, and investigated how manipulating cell metabolism can make cancer more vulnerable to oncolytic viruses

Restricting the ability of cancer cells to metabolise sugar could make oncolytic viruses more effective at attacking them, suggests a study published in the journal Cancer Research.

Viruses that are trained to attack cancer cells – known as oncolytic viruses – can kill tumours without affecting healthy cells nearby. They normally work by invading the cells, multiplying and destroying the tumour from inside. They are currently being tested in clinical trials.

November 30, 2018
Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.

Cancer patients in England have a poorer survival rate than patients in other European countries, according to the Health Foundation.
 
A report by the charity looked at the progress made since the NHS Cancer Plan in 2000, which aimed to see five-year survival rates for cancer in England compare with the best in Europe by 2010.
 
Delays in diagnosis and treatment
 

November 29, 2018
A survey of people working within pharmaceutical industry within and outside the UK found growing negativity about the impact of Brexit on the UK healthcare sector

The majority of pharmaceutical professionals now say Brexit will have a negative impact on the UK healthcare sector, a survey has revealed.
 
Negative sentiment amongst healthcare professionals about the impact of Brexit on the UK healthcare sector has increased over the last three months, according to data and analytics company GlobalData.

November 29, 2018
CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks.

Children with cancer at Great Ormond Street Hospital in London are this week starting a new therapy treatment tailored to target patients’ specific cancer cells.
 
The CAR-T treatment involves collecting and using a patient’s own immune cells to fight the cancer over a number of weeks. 
 
Royal Manchester Children’s Hospital is also offering the immunotherapy treatment, and Newcastle upon Tyne Hospitals NHS Foundation Trust will join next month.
 

November 29, 2018
The discovery could potentially accelerate early diagnosis, speed up drug discovery and lead to advancements in personalised medicines

A technique to get more information from the blood of cancer patients than previously possible has been developed.

The discovery could potentially accelerate early diagnosis, speed up drug discovery and lead to advancements in personalised medicines. The Cancer Research UK-funded study has been published in Advanced Materials.

November 29, 2018
In the EU, regorafenib is indicated for treatment of adult patients with advanced unresectable hepatocellular carcinoma who have been previously treated with sorafenib
Bayer has announced that the National Institute for Health and Care Excellence (NICE) has recommended Stivarga® (regorafenib) as an option for treating advanced unresectable hepatocellular carcinoma (HCC) in adults who have had Nexavar® (sorafenib) only if patientshave Child-Pugh grade A liver impairment and an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.1